PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies ...
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transfo ...
PepGen (PEPG) announced its voluntary decision to temporarily pause the Phase 2 CONNECT2-EDO51 study of PGN-EDO51 in patients with Duchenne ...
Stocktwits on MSN13d
PepGen Sees Fastest Weekly Retail Following Growth Among Biotech Stocks: What's Behind The Buzz?PepGen Inc. (PEPG) shares are on track for their best weekly performance since September 2022, surging 77% as retail interest ...
Hosted on MSN2mon
PepGen stock down 22% on FDA clinical hold (update)S hares of PepGen (NASDAQ:PEPG) were down 22% midday Monday following news the FDA has placed a clinical hold on its Investigational New Drug application to initiate a Phase 2 study for its drug ...
No new safety issues related to PGN-EDO51 have been observed since the Company’s last safety update as of January 23, 2025. “With our 10 mg/kg cohort of CONNECT1 study fully enrolled and data ...
PepGen explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. This release discusses PGN-EDO51 and PGN-EDODM1, investigational therapies ...
"Today, we reported initial results from FREEDOM-DM1, which showed robust splicing correction in patients with DM1 following a single dose of PGN-EDODM1. We believe these data contribute to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback